Adecatumumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | EpCAM |
| Identifiers | |
| CAS Number |
503605-66-1  |
| ATC code | None |
| ChemSpider | none |
| Chemical data | |
| Formula | C6552H10080N1740O2052S46 |
| Molar mass | 147.5 kg/mol |
 (what is this?) (verify) | |
Adecatumumab (MT201) is a recombinant human monoclonal antibody which is used to target tumor cells. It binds to the epithelial cell adhesion molecule (EpCAM - CD326).
Adecatumumab has been used in clinical studies of treatment in prostate[1] and breast cancers.[2]
References
- ↑ Oberneder R, Weckermann D, Ebner B; et al. (October 2006). "A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients". Eur. J. Cancer 42 (15): 2530–8. doi:10.1016/j.ejca.2006.05.029. PMID 16930989.
- ↑ Prang N, Preithner S, Brischwein K; et al. (January 2005). "Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines". Br. J. Cancer 92 (2): 342–9. doi:10.1038/sj.bjc.6602310. PMC 2361858. PMID 15655555.
This article is issued from Wikipedia - version of the Saturday, January 30, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.